FBT holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 6 issuer countries.

FBT's largest investment is Corcept Therapeutics Inc at 5.6% of net assets. Neogenomics Inc COM and Veracyte Inc follow; the three together are 15.82%. Ten companies are 43.17% of the fund; the other 21 share the rest. Among the 721 equity funds measured here, FBT behaves like 28.2 holdings against a median of 42.4 — 1.5 times more concentrated than the median. Across 28 quarterly filings FBT has held roughly steady since 2019-09-30 (28.9 then, 28.2 now). Between the 2026-03-31 and 2026-06-30 filings 2 positions were added and 2 dropped; 18.2% of the weight moved. the United States is the largest country at 84.9% of the portfolio, across 6 countries in the filing.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2019-09-30 and 2026-06-30, FBT went from behaving like 28.9 equally weighted positions to 28.2 — 2% fewer, while its top ten went from 39.83% to 43.17% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

The 15 largest of 31 positions in FBT's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: FBT.csv.gz.

Share of FBT's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of FBT's own filings, 84 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference 0.09 percentage points over 84 months, which is roughly the distributions. Every month with the filing it came from: FBT.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-03-31, $176,735 was out to 1 borrower, 0.01% of net assets.

Cash collateral reported against the loan: 0.01% of net assets, 128.5% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter FBT has filed, with each borrower: FBT.json · all funds.

31 positions became 31: 2 added (5.7% of the fund at the later date), 2 dropped (8.2% at the earlier date). Half the sum of all weight changes, a turnover proxy: 18.2%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of FBT compared this way, as a feed: changes.xml · all funds: filings received.

New: ARROWHEAD PHARMACEUTICALS INC (3.37%), ADMA BIOLOGICS INC (2.33%). Gone: Moderna Inc (5.26%), Acadia Pharmaceuticals Inc (2.95%).

99.95% equity, 0.05% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of FBT (28.2). Same filings, same arithmetic. Position in this list says nothing about which fund is better.